Project Overview
This program will see all children in NSW diagnosed with cancer eligible to participate in a genetic predisposition screening study. It will allow us to identify gene variants of possible clinical significance and to identify families susceptible to the development of cancer and rare diseases. This program will establish the foundation for access to the appropriate services for the management of risk, preventative measures and treatment for children and families with a genetic predisposition to cancer. Through this program, New South Wales will take a significant lead to the international knowledge of gene variants, leading to new clinical agenda to benefit patients and the wider community.
Collaborations
- Children’s Cancer Institute (Australia)
- Kids Cancer Centre Sydney Children’s Hospital, Randwick, Sydney Children’s Hospitals Network (Australia)
- Children’s Cancer Research Unit, Cancer Centre for Children, Department of Genetics, Children’s Hospital Westmead, Sydney Children’s Hospitals Network (Australia)
- Zero Childhood Cancer national and international partners network (8 hospitals, >20 research institutes), incl. all three NSW Paediatric Oncology Centres, Children’s Hospital Westmead, Sydney Children’s Hospitals Network, John Hunter Children’s Hospital, and Sydney Children’s Hospital, Randwick (Australia)
- Hereditary Cancer Centre, Prince of Wales Hospital, Randwick (Australia)
- Familial Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital (Australia)
- Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research (Australia)
- Behavioural Sciences Unit, Kids Cancer Centre, Randwick, University of NSW School for Women’s and Children’s Health (Australia)
- Children’s Medical Research Institute, Children’s Cancer Institute, and CHW Functional genomics researchers
- University of NSW (Australia)
- University of Sydney (Australia)
- Consumer representative groups
